高通量CRISPR-Cas13 SARS-CoV-2检测方法
本研究开发了一种基于CRISPR的高通量SARS-CoV-2 RNA检测方法,采用SHERLOCK技术,可在无需核酸提取的情况下直接检测拭子或唾液样本,384孔板格式且1小时内出结果。该方法与CDC RT-qPCR检测结果高度一致,适用于高复杂度实验室快速提升检测能力。
要点
- 基于SHERLOCK的高通量SARS-CoV-2检测可在1小时内完成384孔板检测。
- 直接样本(拭子或唾液)无需核酸提取即可检测,与RT-qPCR结果高度一致。
- 该方法适合高复杂度实验室利用简单设备快速扩大检测通量。
核心结论
- 该高通量检测方法可对有或无核酸提取的患者样本检测SARS-CoV-2,与RT-qPCR方法高度一致。
研究设计与样本
- 开发基于CRISPR的SHERLOCK检测方法,采用384孔格式,直接检测拭子或唾液样本。
- 使用105例既往经FDA紧急使用授权方法检测的残余SARS-CoV-2样本进行评估。
主要发现
- 结合磁珠提取时,高通量SHERLOCK检测与CDC RT-qPCR 100%一致(n=60)。
- 直接样本添加时,高通量检测与CDC RT-qPCR直接法100%一致(n=45)。
- 直接唾液样本添加时,阴性符合率100%(15/15,95% CI: 81.8-100%),阳性符合率88%(15/17,95% CI: 63.6-98.5%)。
关键数值与推荐
- 检测结果在<1小时内提供。
- 结合磁珠提取与CDC RT-qPCR一致性为100%(n=60)。
- 直接样本添加与CDC RT-qPCR直接法一致性为100%(n=45)。
- 直接唾液样本阴性符合率100%(15/15,95% CI: 81.8-100%),阳性符合率88%(15/17,95% CI: 63.6-98.5%)。
临床怎么用
- 高复杂度实验室可利用简单设备快速提升SARS-CoV-2检测通量。
- 可直接使用拭子或唾液样本,无需核酸提取,简化检测流程。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The ability to control the spread of COVID-19 continues to be hampered by a lack of rapid, scalable, and easily deployable diagnostic solutions. METHODS: We developed a diagnostic method based on CRISPR (clustered regularly interspaced short palindromic repeats) that can deliver sensitive, specific, and high-throughput detection of Sudden Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). The assay utilizes SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) for the qualitative detection of SARS-CoV-2 RNA and may be performed directly on a swab or saliva sample without nucleic acid extraction. The assay uses a 384-well format and provides results in <1 hour. RESULTS: Assay performance was evaluated with 105 (55 negative, 50 positive) remnant SARS-CoV-2 specimens previously tested using Food and Drug Administration emergency use authorized assays and retested with a modified version of the Centers for Disease Control and Prevention (CDC) quantitative PCR with reverse transcription (RT-qPCR) assay. When combined with magnetic bead-based extraction, the high-throughput SHERLOCK SARS-CoV-2 assay was 100% concordant (n = 60) with the CDC RT-qPCR. When used with direct sample addition the high-throughput assay was also 100% concordant with the CDC RT-qPCR direct method (n = 45). With direct saliva sample addition, the negative and positive percentage agreements were 100% (15/15, 95% CI: 81.8-100%) and 88% (15/17, 95% CI: 63.6-98.5%), respectively, compared with results from a collaborating clinical laboratory. CONCLUSIONS: This high-throughput assay identifies SARS-CoV-2 from patient samples with or without nucleic acid extraction with high concordance to RT-qPCR methods. This test enables high complexity laboratories to rapidly increase their testing capacities with simple equipment.
引用
- Manning BJ, Khan WA, Peña JM, et al. High-Throughput CRISPR-Cas13 SARS-CoV-2 Test. Clin Chem. 2021. PMID: 34718481. doi:10.1093/clinchem/hvab238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。